Impilo invests in Pelago Bioscience – a fast-growing drug discovery research partner
STOCKHOLM, Sweden, 16 August 2023 – Impilo invests in Pelago Bioscience AB (“Pelago” or the “Company”) and enters a partnership with the Founders to accelerate platform expansion. Pelago is a fast-growing drug discovery focused contract research organisation (“CRO”) with a service offering centered around its patented CEllular Thermal Shift Assay (CETSA®) technology. CETSA® provides unique value to customers in accelerating drug discovery projects given its ability to quantify how a drug compound binds to its intended target and perturb the biology in whole-cell physiological conditions.